More than 250 vaccines are in development, for diseases including cancers, allergies and Alzheimer’s.1
More than 250 vaccines are in development, for diseases including cancers, allergies and Alzheimer’s.1
Pharmaceutical companies are innovating for the next generation of vaccines with more than 250 vaccines2 in development for the prevention or treatment of disease.
New technologies are also helping the pharmaceutical industry to find potential new vaccines.
74% of the COVID-19 vaccines in clinical trials are being developed by the pharmaceutical industry.3
Biopharmaceutical companies have deep scientific knowledge gained from decades of virus research, which is helping dramatically improve the chances of developing an effective vaccine for COVID-19.4
69 vaccines are in Phase III development, including 10 for cancer. 2
Over 250 vaccines are in development for the prevention or treatment of disease across all phases of the research development cycle.1
.jpg)
Advances in our understanding of disease coupled with scientific and technological progress are helping the pharmaceutical industry to design more effective vaccines, ones with a better immune response or vaccines that can be easier or quicker to manufacture.
At the cutting-edge of vaccines development, researchers are looking at:
The global vaccine R&D effort in response to the COVID-19 pandemic has been unprecedented in terms of scale and speed.
The pharmaceutical industry is playing a critical role in research, development and manufacturing.
A range of cutting edge technologies are being used to help speed up the process while maintaining levels of safety:
Whole-pathogen viruses
Viral vector technology
Nucleic Acid vaccines
Other vaccines
